rs613084 — CPT1A CPT1A carnitine shuttle variant

CPT1A — The Rate-Limiting Gateway for Fat Burning

Your liver burns fat by routing long-chain fatty acids into mitochondria — the cellular power plants. But fatty acids can't cross the inner mitochondrial membrane on their own. They need a molecular escort. That escort is the carnitine shuttle¹¹ carnitine shuttle
a two-enzyme system that attaches a carnitine molecule to fatty acids, enabling mitochondrial entry, and the enzyme that initiates it — carnitine palmitoyltransferase 1A (CPT1A) — is the rate-limiting bottleneck for all hepatic fat oxidation.

rs613084 is an intronic variant that acts as a cis-regulatory switch for CPT1A expression in liver tissue. Your genotype here influences how much CPT1A your liver produces, which in turn governs how efficiently you clear long-chain fats, influence circulating triglyceride levels, and generate HDL cholesterol.

The Mechanism

CPT1A sits on the outer mitochondrial membrane and catalyzes the acylcarnitine²² acylcarnitine
the carnitine-linked form of a fatty acid that can traverse the mitochondrial membrane conversion step. Its activity is tightly regulated by malonyl-CoA³³ malonyl-CoA
a metabolic intermediate that rises when energy is plentiful, signaling the cell to store rather than burn fat, which binds the enzyme's N-terminal domain and acts as an allosteric brake. When CPT1A expression is higher, more enzyme is available to handle fat-burning demand even under partial malonyl-CoA inhibition; when expression is lower, long-chain fatty acids back up in the cytoplasm and are re-esterified as triglycerides rather than oxidized.

rs613084 lies within CPT1A intron 1 — a genomic region that, based on parallel methylation research in the GOLDN study⁴⁴ GOLDN study
Genetics of Lipid Lowering Drugs and Diet Network — a large family-based study of European-ancestry adults, appears to be a major regulatory hub for CPT1A transcription. Two CpG sites in this same intron associate with fasting triglycerides at genome-wide significance (p=5.3×10⁻¹⁴) and with VLDL-C, adiponectin, insulin, and HOMA-IR. The A allele at rs613084 has been shown to correlate with higher CPT1A transcript levels in a cis-eQTL analysis of Mexican American families (SAFHS cohort).

The Evidence

The primary genetic evidence for rs613084 comes from the GOCADAN study⁵⁵ GOCADAN study
Genetics of Coronary Artery Disease in Alaska Natives, n=761 Alaskan Eskimos, where rs613084 emerged as one of three independent CPT1A variants significantly associated with estimated delta-5 desaturase (D5D) activity — the rate-limiting enzyme for ω-3 and ω-6 fatty acid conversion — at p=6.7×10⁻⁵ for HDL-C and reaching p values as low as 1.6×10⁻⁹ for erythrocyte D5D activity. The A allele associated with higher D5D activity and elevated HDL-C. Importantly, the CPT1A expression association was replicated in Mexican Americans⁶⁶ replicated in Mexican Americans
San Antonio Family Heart Study (SAFHS), a large independent family-based cohort of Mexican-American adults (p=1.14×10⁻⁶²), making this one of the strongest cis-eQTL signals for CPT1A in liver-relevant tissue and confirming the finding across ethnic groups.

The indirect link between CPT1A expression and D5D activity is thought to reflect a shared regulatory network: both enzymes participate in fatty acid flux decisions in the liver, and CPT1A activity influences the availability of fatty acid substrates for FADS-family desaturases. Higher CPT1A expression means more substrate is diverted toward oxidation, which alters the pool available for desaturation and incorporation into phospholipids and lipoproteins — explaining the observed HDL-C effect.

Practical Actions

The A allele at rs613084 is associated with modestly higher CPT1A expression and more efficient hepatic fatty acid oxidation, reflected in higher HDL-C. This variant has no drug interactions and is not pathogenic. Its primary practical relevance is in optimizing dietary fat composition and supporting the carnitine shuttle that CPT1A depends on.

Long-chain fatty acids require L-carnitine as a cofactor for CPT1A-mediated transport. Individuals with lower CPT1A expression (CC genotype) have less enzymatic reserve for fat oxidation and may benefit more from dietary and supplementation strategies that support carnitine availability.

Interactions

rs613084 acts within the same functional network as rs3019594 and rs11228368 — two other independent CPT1A intronic variants identified in the GOCADAN study. Together these three SNPs tag distinct haplotype blocks across the CPT1A intron 1 regulatory region. They may interact additively on expression.

The Arctic-prevalence CPT1A P479L variant (rs80356779) — a missense variant with reduced malonyl-CoA sensitivity and lower catalytic activity — is a distinct functional allele in the same gene with independent population genetics and a separate biological mechanism. Compound effects of rs613084 with rs80356779 have not been formally studied but would be relevant in Arctic-ancestry populations carrying both.